New analysis shows Gilenya (Novartis) offers significant benefits in Multiple Sclerosis over four years of treatment

Analysis of three Phase III trials shows Gilenya (fingolimod), from Novartis, offers significant benefits in patients with Multiple Sclerosis after four years of treatment. A new analysis of over 3,600 patients from three large Phase studies (TRANSFORMS, FREEDOMS, and FREEDOMS II) shows that Gilenya offers a significant reduction in the rate of brain volume loss vs. a comparator � by 32 percent (p<0.001) compared to avonex in transforms and by 35 percent p><0.001) in the freedoms study and by 33 percent p><0.001) in the freedoms ii. this is consistent with previously reported results.>

The data also showed that brain volume, at baseline, consistently correlated with the level of disease severity and disability. Additionally, a recent subgroup analysis of FREEDOMS II supports the efficacy of Gilenya, showing consistently reduced annualized relapse rates (ARR) compared to placebo in patients with relapsing-remitting MS. Data was presented at the 65th annual meeting of the American Academy of Neurology.